06 August 2008

Malaria drug scare for Africa

More than a third of malaria pills tested failed quality tests, according to a report.

More than a third of malaria pills tested failed quality tests, according to a report.

Tests of 195 different packs of malaria drugs sold in six African cities showed 35 percent of them either did not contain high enough levels of active ingredient or did not dissolve properly.

"Our study shows that efforts to increase access to quality anti-malarial drugs in Africa are increasingly important," Dr Roger Bate of the American Enterprise Institute, who led the study, said in a statement.

"Substandard drugs not only endanger lives today, but also jeopardise future malaria treatment strategies by accelerating parasite resistance."

Dr Marcus Brauer from Medi-Travel International in Cape Town believes that the problem is two-fold. "People are accessing medicines from a pharmacy directly and not via a medical service provider; and they are not always given the most appropriate treatment or preventative medicine," comments Brauer.

In addition, "the market for antimalarial medicines is a big one in African countries that have malaria, and as such is an easy target for the importation and selling of substandard or in fact counterfeit and ineffective treatment. Even medicines given as treatment in hospitals have been shown to occasionally be ineffective in African countries," he says.

200 000 preventable deaths
Substandard antimalarial drugs are the cause of an estimated 200 000 avoidable deaths each year, Bate and colleagues reported in the Public Library of Science journal PLoS ONE.

The researchers said they sent agents to pose as customers at randomly selected pharmacies. They simply asked for anti-malarial drugs and the manufacturers were not named in the study.

They said a third of the packs they tested contained only one drug, an artemisinin-based drug. The World Health Organization has asked countries to stop using these so-called monotherapies.

"The high persistence of substandard drugs and clinically inappropriate artemisinin monotherapies in the private sector risks patient safety and, through drug resistance, places the future of malaria treatment at risk globally," the researchers wrote.

Of these one-drug packs, 42 percent failed the quality tests, Bate and colleagues reported.

Only purchase approved drugs
"The World Trade Organization, which sets the rules of global commerce, should enact rules prohibiting the international trade in artemisinin monotherapies and reducing the tariffs on proper medicines to zero," they wrote.

"These incidents argue strongly for a rule against purchasing locally manufactured medicines, except where those medicines have received regulatory approval from a developed country or the WHO's prequalification scheme," they added.

Brauer suggest South African travellers should see a registered travel clinic for advice on the choice and indication for malaria preventative tablets. "Purchase your anti-malarial medicine in South Africa where we have stringent controls on medicine standards via the Medicines Control Council," he advises.

"When treating malaria one should not rely on a single drug regimen only," Brauer warns. "Treatment should always consist of two medications."

The WHO estimates that malaria kills 1.3 million people each year, mostly children under age five.

The disease, transmitted by mosquitoes carrying tiny malaria parasites, has been very hard to fight. The parasites have evolved resistance to the drugs and the mosquitoes have developed resistance to pesticides.

Combinations of drugs work better to kill the parasites and using a cocktail, as well as proper dosing, helps prevent the development of resistance.

(Reuters Health and Wilma Stassen, Health24)

May 2008

Read more:
Two malaria drugs scrapped
New way to block malaria


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.